A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMediLink Therapeutics (Suzhou) Co., Ltd.
About this trial
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Eligibility criteria
Qualifiers
Age ≥ 18 years old.
Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.
ECOG PS score is 0 or 1.
Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.
Disqualifiers
Suitable for local curative treatment.
Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).
Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.
Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) [anti-PD-(L)1] or other immune checkpoint inhibitors.
Trial design
Treatments tested in this trial
- YL201
- Ivonescimab
Treatment groups
260 Participants
are divided into 2 treatment groupsLocations
1Sun Yat-sen University Cancer Center510060, GuangzhouGuangdong, China
Sponsors and collaborators
MediLink Therapeutics (Suzhou) Co., Ltd.
Lead sponsor
Akesobio
Collaborator
Source ClinicalTrials.gov